- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07765563
Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
In brief, review of the medical literature showed two comparable studies out of India and Spain suggesting that expired allergen series may be used beyond their labeled expiry dates, with some variability noted amongst duration of expiry, that the investigators will also aim to analyze.
Regarding allergen stability, there were also several studies focused on this domain. The European Society of Contact Dermatitis (ESCD) released guidelines in 2015, outlining optimal methods for allergen storage such as storage at 4 degrees celsius and strict protection from ultraviolet light exposure. While most allergens are dispersed in petrolatum (white soft paraffin), some substances are better tested in solutions such as water (aqueous) or ethanol. Several allergens with high vapour pressure require more frequent renewal and strict storage conditions such as fragrance chemicals, acrylates and isocyanates. Other substances such as glutaraldehyde in petrolatum (pet.) and formaldehyde in aqueous solution (aq.) are susceptible to instability and deterioration. An additional study assessed volatility over time of several select compounds and described high volatility in acrylates, glutaraldehyde, and fragrances, while describing partial volatility of formaldehyde and low volatility of nickel sulfate.
Study participants will include all eligible adults seen in patch testing clinic who maintain an indication for patch testing and consent to participation. The study will be utilizing 10 allergens from the North American Contact Dermatitis Group (NACDG) 80 Series for inclusion in the study.
The allergen selections are primarily based on compounds with a higher likelihood for volatility, in addition to inclusion of two comparator compounds with lower volatility. Expiration intervals include 1 year, 2 years, 3 years, and 4 years. The compounds selected are as follows, including their dispersion compound: nickel sulfate hexahydrate (5% pet.), cobalt (II) chloride hexahydrate (2.5% pet.), hydroperoxides of linalool (1% pet.), hydroperoxides of limonene (0.3% pet.), fragrance mix 1 (8.0% pet.), myroxylon pereirae resin (balsam of Peru) (25.0% pet.), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) (0.02% aq.), formaldehyde (2.0% aq.), tixocortol-21-pivalate (1.0% pet.), and budesonide (0.1% pet.).
The patch testing results will be compared to corresponding non-expired allergens from the same manufacturer with the same preparation tested simultaneously. Both series will be placed simultaneously in differing locations on the participant's back, ensuring both are placed in sun protected areas with no underlying dermatitis.
Once in clinic, standard patch test series are applied on patch testing day, with the participant instructed not to shower or scratch the area throughout testing. At 48h, the patches are removed and photos are taken of the participant's back which are sent to the Dermatologist for virtual reading. At either 96h or 120h, the participant returns to the clinic for final reading. Both morphology and intensity of positives are graded on a standard patch test scale (irritant reaction), +/- for doubtful, + for erythema and infiltration, ++ for edematous or vesicular and +++ for spreading, bullous or ulcerative. Positive allergens scored + or greater are considered a true allergic contact allergen and assessed for relevance based on clinical context. The Dermatologist provides information sheets on all positive allergens, counsels on the relevance to their clinical history and allergen avoidance going forward, as well as providing the participant with a safe product list via the ACDS Contact Allergen Management Program (CAMP) database.
The investigators are aiming for enrolment of 100 participants which should theoretically provide the study with at least 5-10 participants testing positive to each of the four listed allergens with higher volatility and 20+ participants testing positive to the allergens with lower volatility. The investigators are aiming to assess concordance between expired and non-expired allergen reactions (positive vs negative), in addition to agreement in reaction intensity, differences in morphology, rates of false positives/negatives compared to control and concordance of irritant reaction between interventions.
The study will serve to lend valuable evidence as to whether expired allergens maintain clinical utility and could serve to reduce product waste, lower the economic burden and further improve accessibility of patch testing for use in resource limited settings.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Dylan Hollman, Medical Doctor
- Número de telefone: 1-403-955-8444
- E-mail: dylan.hollman@ucalgary.ca
Locais de estudo
-
-
Alberta
-
Calgary, Alberta, Canadá, T2T 5C7
- Richmond Road Diagnostic Treatment Centre
-
Contato:
- Dylan Hollman, Medical Doctor
- Número de telefone: 1-403-955-8444
- E-mail: dylan.hollman@ucalgary.ca
-
Investigador principal:
- Laurie Parsons, Medical Doctor
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adults (age 18 years or older) referred for patch testing.
Exclusion Criteria:
- Relative or absolute contraindication to patch testing
- Wide spread dermatitis prior to patch placement
- Inability to return to clinic for reading of results
- Patient non-consenting
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Enrolled Study Participants
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
|
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patch Testing Response (Positive/Negative) Concordance Rate (%) Between Non-Expired and Expired Allergens
Prazo: Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
|
Each allergen will be graded on response using a standard patch test scale including: irritant reaction ['IR'], '+/-' for doubtful, '+' for erythema and infiltration, '++' for edematous or vesicular and '+++' for spreading, bullous or ulcerative response that will be graded by the participating Dermatologist.
Reactions graded '+', "++", or "+++" are consider a positive result.
Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e.
Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 92% of cases, the Nickel allergen in the non-expired and expired patches were both found to both be either positive or negative while in 8% of cases the response differed per the scale listed above.)
|
Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Reaction/Morphology Scoring Concordance (%)
Prazo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
For each positive allergen, severity (i.e.
'+/-', '+', '++', "+++") and morphology (i.e.
erythema, infiltration, edematous, vesicular, bullous, ulcerated) will be recorded.
Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e.
Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 70% of cases, the Nickel allergen in the non-expired and expired patches were both found to have the exact same severity and morphology, while in 30% of cases the severity and/or morphology differed per the scale listed above.)
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
|
Stability Concordance (%) Amongst Mediums
Prazo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Each allergen is suspended within a medium, either petrolatum or aqueous solution.
Not only will concordance (%) of positive and negative reactions be assessed amongst allergens and compared between non-expired and expired, but also between mediums to determine if there is a difference in stability over time amongst mediums used to determine if particular mediums result in degradation over time.
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
|
Irritant Reaction Rates (%)
Prazo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Final patch reading will score reactions on a standarized scale, with irritant reaction representing a negative reaction.
However, we will compare rates and concordance (%) of irritant reactions between allergens to determine if their is reproducibility, or if expired allergens result in differing rates of irritant reactions.
(i.e.
Nickel sulfate allergen was shown to have a 50% increased rate of irritant reactions between the expired to non-expired allergens, meaning that Nickel resulted in an irritant reaction in 6 cases of the expired Nickel and 4 cases of the non-expired Nickel, suggesting that expired Nickel allergens may become more irritating over time, resulting in more irritant reactions.
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Laurie Parsons, Medical Doctor, University Of Calgary
Publicações e links úteis
Publicações Gerais
- Houle MC, DeKoven JG, Atwater AR, Reeder MJ, Warshaw EM, Pratt MD, Belsito DV, Adler BL, Silverberg J, Yu J, Botto N, Mowad CM, Dunnick CA, Taylor JS. North American Contact Dermatitis Group Patch Test Results: 2021-2022. Dermatitis. 2025 Sep-Oct;36(5):464-476. doi: 10.1089/derm.2024.0474. Epub 2025 Apr 24.
- Schalock PC, Dunnick CA, Nedorost S, Brod B, Warshaw E, Mowad C, Scheman A; American Contact Dermatitis Society Core Allergen Series Committee. American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis. 2020 Sep-Oct;31(5):279-282. doi: 10.1097/DER.0000000000000621.
- Siegel PD, Fowler JF, Law BF, Warshaw EM, Taylor JS. Concentrations and stability of methyl methacrylate, glutaraldehyde, formaldehyde and nickel sulfate in commercial patch test allergen preparations. Contact Dermatitis. 2014 May;70(5):309-15. doi: 10.1111/cod.12169.
- Mowitz M, Svedman C, Zimerson E, Bruze M. Fragrance patch tests prepared in advance may give false-negative reactions. Contact Dermatitis. 2014 Nov;71(5):289-94. doi: 10.1111/cod.12300. Epub 2014 Sep 18.
- Mose KF, Andersen KE, Christensen LP. Stability of selected volatile contact allergens in different patch test chambers under different storage conditions. Contact Dermatitis. 2012 Apr;66(4):172-9. doi: 10.1111/j.1600-0536.2011.02035.x.
- Goon AT, Bruze M, Zimerson E, Sorensen O, Goh CL, Koh DS, Isaksson M. Variation in allergen content over time of acrylates/methacrylates in patch test preparations. Br J Dermatol. 2011 Jan;164(1):116-24. doi: 10.1111/j.1365-2133.2010.10087.x.
- Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, Cannavo A, Gimenez-Arnau A, Goncalo M, Goossens A, John SM, Liden C, Lindberg M, Mahler V, Matura M, Rustemeyer T, Serup J, Spiewak R, Thyssen JP, Vigan M, White IR, Wilkinson M, Uter W. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015 Oct;73(4):195-221. doi: 10.1111/cod.12432. Epub 2015 Jul 14.
- Rodrigues Barata AR, Haroun-Diaz E, Conde-Salazar Gomez L. Can expired TRUE Test(R) be used for patch testing? Contact Dermatitis. 2014 Jun;70(6):381-2. doi: 10.1111/cod.12175. No abstract available.
- Mahajan VK, Chauhan PS, Mehta KS, Sharma A, Chowdhary B, Dhattarwal N, Sharma H, Chandel M, Verma YR. Patch testing with expired Indian patch test kits: Results of a pilot study. Indian J Dermatol Venereol Leprol. 2022 Mar-Apr;88(2):188-195. doi: 10.25259/IJDVL_390_19.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Hipersensibilidade
- Doenças de pele
- Doenças de Pele, Eczematosas
- Hipersensibilidade, Retardada
- Dermatite
- Doenças da Pele e do Tecido Conjuntivo
- Dermatite de contato
- Dermatite Alérgica de Contato
- Fenômenos fisiológicos circulatórios e respiratórios
- Mecânica respiratória
- Respiração
- Fenômenos fisiológicos respiratórios
- Exhalation
Outros números de identificação do estudo
- REB26-0539
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .